Loading clinical trials...
Loading clinical trials...
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Conditions
Interventions
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Docetaxel
+2 more
Locations
217
United States
Georgetown University Medical Center Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Emory University; Winship Cancer Institute
Atlanta, Georgia, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Duke Cancer Center
Durham, North Carolina, United States
Bon Secours - St. Francis Hospital
Greenville, South Carolina, United States
Vanderbilt-Ingram Cancer Ctr
Nashville, Tennessee, United States
Start Date
January 13, 2015
Primary Completion Date
March 13, 2017
Completion Date
November 8, 2018
Last Updated
August 1, 2019
NCT07061964
NCT04235764
NCT03375307
NCT00026884
NCT04585750
NCT07050771
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions